GlassScriptPhysician profile
Stephen Joseph Park
NPI 1649407289
$5,315.73
in general payments reported to CMS, 2019-2025
32 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $113 · 2021: $161 · 2022: $568 · 2023: $1,018 · 2024: $1,501 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.54 | 2019-2025 | |
| Janssen Biotech, INC. | $643.33 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.29 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $371.60 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $315.14 | 2019-2025 | |
| Qol Medical, LLC | $263.10 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $197.94 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $188.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Fresenius Kabi USA, LLC | $186.43 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Penumbra, INC. | $129.31 | 2019 | |
| Lilly USA, LLC | $119.33 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $108.92 | 2019-2025 | Clenpiq, Rebyota |
| Genzyme Corporation | $99.75 | 2025 | |
| Ironwood Pharmaceuticals, INC | $98.45 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.68 | 2020-2024 | Dificid, Zinplava |
| Genentech USA, INC. | $85.15 | 2019 | |
| Intercept Pharmaceuticals, INC. | $74.66 | 2019-2024 | |
| Braintree Laboratories, INC. | $67.58 | 2020-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $65.00 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $53.55 | 2024-2025 | Injectafer |
| Ardelyx, INC. | $46.03 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $45.97 | 2023-2024 | |
| Ethicon US, LLC | $40.38 | 2020-2022 | |
| Redhill Biopharma INC. | $32.71 | 2023 | Talicia, Aemcolo, Movantik |
| Phathom Pharmaceuticals, INC. | $32.60 | 2024-2025 | Voquezna |
| Amgen INC. | $26.44 | 2023 | Amjevita, Avsola |
| Celltrion USA INC. | $24.22 | 2025 | Vegzelma |
| Boston Scientific Corporation | $22.88 | 2023 | Acquire |
| Evoke Pharma, INC. | $18.99 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $11.52 | 2021 | |
| Allergan, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.